BrainStorm Cell Therapeutics Inc. is a clinical stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The company s current primary targets are Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig s disease and Parkinson s disease PD . These devastating diseases have no treatment options and as such represent highly unmet medical needs. Upon completion of BrainStorm s clinical trials program and regulatory approvals, this novel therapy will provide compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By redirecting the inherent regenerative capacities of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable healthcare institutions and society at large to realize massive savings in treatment and care costs. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
Quote | Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Last: | $0.5255 |
---|---|
Change Percent: | -1.22% |
Open: | $0.547 |
Close: | $0.532 |
High: | $0.5551 |
Low: | $0.52 |
Volume: | 144,409 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
2024-04-17 03:25:55 ET More on BrainStorm Cell Therapeutics BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics His...
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...
Message Board Posts | Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $BCLI News Article - BrainStorm Cell Therapeutics Strengthens Leadership Team with Appo | whytestocks | investorshangout | 04/24/2023 12:25:46 PM |
Our valuation remains at $20 per share. | midastouch017 | investorshub | 04/06/2023 5:24:37 AM |
From Zacks: | Fmello | investorshub | 04/04/2023 8:46:30 PM |
https://www.neurologylive.com/view/critical-importance-fda-adcomm-meeting-als-th | Fmello | investorshub | 04/03/2023 8:50:04 PM |
$BCLI stock rose 80.33% in five days! | Fmello | investorshub | 04/01/2023 3:46:34 PM |
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegener...
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS PR Newswire NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes ...